NASDAQ · KYNB

Kyntra Bio, Inc.

$7.05 +$0.02 (+0.28%) 1D Market open
Charting by TradingView

Key Metrics

$28.46M
Market cap
0.17×
P/E · TTM
$7.44M
Revenue · TTM
$163.62M
Net income
EPS · TTM $40.52
Dividend yield —
Free cash flow −$21.40M
Beta · 1Y 1.17
EBITDA · TTM −$56.80M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 24
    The stock moved -9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24
  • Feb 6
    The stock moved +9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$28.46M
Enterprise value$8.20M
Shares outstanding4.0M
52-wk range$6.32 – $9.70
Avg volume · 20D24.1K
Net cash $20.26M
Book value / share$-10.85
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Kyntra Bio, Inc.
IPO dateNov 14, 2014
Employees34

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E0.17
P/S3.83
P/FCF—
EV/EBITDA—
EV/Sales1.10
Graham №—

Profitability

Gross —
Operating -768.8%
Net 2,199.4%
FCF -287.7%
ROE / ROIC -121.5% · 101.9%

Financial Health

Current ratio3.61
Quick ratio3.48
Debt / equity-1.71
Debt / EBITDA -1.32
Net cash $20.26M
Working capital$73.24M

Cash Flow · TTM

Operating CF −$21.38M
Capex −$22.00K
Free cash flow −$21.40M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-22.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings